The oral Janus kinase (JAK) 1/2 inhibitor ruxolitinib may improve outcomes in patients with steroid-refractory or steroid-dependent chronic graft-vs-host disease (GVHD) compared with current best available therapy (BAT), according to results of the phase III REACH3 study presented at ASH 2020.
Dr. Jennifer Woyach, Dr. Michael Wang, Dr. Jennifer Brown, 20210128024132
Acalabrutinib, a next-generation, highly selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor, is approved for treatment of chronic lymphocytic leukaemia (CLL) and mantel cell lymphoma (MCL) in Hong Kong. At the 62nd American Society of Hematology Annual Meeting and Exposition (ASH 2020), researchers presented data from a pooled analysis of four trials showing a low risk of cardiac adverse events (AEs) in CLL patients treated with acalabrutinib, while another study demonstrated tolerability and efficacy of acalabrutinib-based triple combination regimens in patients with treatment-naïve (TN) or relapsed/refractory (R/R) CLL. In patients with R/R MCL, extended follow-up data presented at ASH 2020 confirmed the safety and sustained efficacy of acalabrutinib that supports its long-term use.
A combination therapy of umbralisib + ublituximab (U2) significantly improves progression-free survival (PFS) inpatients with chronic lymphocytic leukaemia (CLL) compared with obinutuzumab + chlorambucil (O+Chl), according to the UNITY-CLL* study presented at ASH 2020.
Patients with coronavirus disease 2019 (COVID-19) who have haematologic malignancies have a 28 percent mortality rate, according to data collected from 250 patients by the ASH Research Collaborative COVID-19 presented at the 62nd American Society of Hematology Annual Meeting and Exposition (ASH 2020).
In patients newly diagnosed with immune thrombocytopenia (ITP), the first-line combination treatment of mycophenolate and corticosteroids was effective and well tolerated compared with corticosteroids alone, results of the UK-based Flight* trial showed.
While it is well known that COVID-19 illness is associated with coagulopathy, the optimal anticoagulation strategy remains elusive, and two studies presented at the ASH 2020 Congress further add to the growing debate on the appropriate anticoagulant dose for hospitalized patients with COVID-19.
An anticoagulation strategy based on blood D-dimer level as a biomarker for clotting risk may help improve survival of patients hospitalized with COVID-19, according to a study presented during the ASH 2020 Meeting.
Dabigatran was similarly effective as standard of care (SOC) in resolving thrombus and preventing recurrent venous thromboembolism (VTE), without raising the risk of bleeding in children, according to the DIVERSITY trial presented at ASH 2020 — thus providing a potential oral alternative to standard of care for the paediatric population.
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.